The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > BUSINESS
BUSINESS
- Eisai Eyes 1 Trillion Yen in Leqembi Global Sales in FY2030: CEO
March 10, 2023
- Xospata Fails in PIII for Post-Transplant AML Maintenance Therapy: Astellas
March 10, 2023
- Shingo Iwamoto Sworn in as New Chief of Nichi-Iko; Tamura Bows Out
March 9, 2023
- Silgard 9 Approved for 2-Dose Schedule: MSD
March 9, 2023
- Nipro Curbed Shipments of 28 APIs/40 Products as Precaution for Rush Demand
March 9, 2023
- Opdivo Tops Japan Drug Ranking for 14 Months Running: Encise
March 8, 2023
- Japan Ethical Drug Sales Grow 3.5% in January: Crecon
March 8, 2023
- Teva Takeda Prepping for Listing of Allermist AG in June
March 8, 2023
- Kyorin Out-Licenses Vibegron to Sumitomo in 5 Asian Markets
March 7, 2023
- Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
March 7, 2023
- Drug Makers Wary of Rush Demand Tied to Unprofitability Re-Pricing, Some Curb Orders
March 7, 2023
- Teijin Grants Global Rights for Kidney Disease Med to Novartis
March 7, 2023
- FDA Accepts Eisai’s Lecanemab Application for Early July Target
March 6, 2023
- Generic Makers See Milder Cuts in FY2023 Revision, Nipro to Get 1%-Plus Net Hike: Jiho Poll
March 6, 2023
- 2023 Price Cut for Top-Tier, 2nd-Tier Firms at 1-4%, Tsumura Only Original Drug Maker to See Net Rise: Jiho Poll
March 6, 2023
- Sumitomo Pharma Drops Cancer Drug Candidate Dubermatinib
March 6, 2023
- Alfresa Pharma Gets Japan Rights to Keio Biotech’s ALS Drug
March 3, 2023
- Biogen Japan, Eisai to End MS Copromotion Pact in Japan
March 3, 2023
- Neil MacGregor Takes Over as President of Amgen Japan
March 2, 2023
- Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…